Hosseinion Warren 4

What Happened

• Hosseinion Warren, President and director of Nutex Health (NUTX), made an open-market purchase of 252 shares on March 19, 2026 at $94.07 per share, a total cost of $23,706. The filing also reports an exercise/conversion of 3,656 derivative shares dated March 10, 2026 at $0.00 (no cash paid), which the footnote clarifies relates to restricted stock units (RSUs) reported earlier.
• The purchase is a straightforward buy (a net acquisition) rather than a sale. The derivative conversion/award did not involve proceeds and appears tied to an RSU grant/vesting.

Key Details

• Purchase: 252 shares @ $94.07 on 2026-03-19 — total ~$23,706.
• Derivative conversion/exercise: 3,656 shares @ $0.00 on 2026-03-10 (code M).
• Footnote: This Form 4 corrects the number of RSUs beneficially owned following the RSU grant previously reported in a Form 4 filed March 11, 2026 (relating to the March 10 transaction).
• Shares owned after the transactions: not specified in this filing (see the corrected RSU disclosure noted in the footnote).
• Filing timeliness: This filing (filed 2026-03-23) corrects a prior report and is a routine correction; the March 19 purchase was reported within the required window given the weekend.

Context

• For retail investors: a direct purchase by a company insider is often viewed as a positive signal because the insider is adding to their stake. The reported derivative conversion appears to be RSU-related (no cash paid) rather than a cashless sale or monetization event, and the filing corrects prior RSU reporting rather than announcing a new, unusual transaction.